Zymeworks News and Activities

Zymeworks is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Zymeworks is a company listed under the stock ticker ZYME (CA).

Acquisition, funding and merger involving Zymeworks.

• Zymeworks has announced the acquisition of Theravance Biopharma  (posted on June 29 2026).

View the org chart displaying its 42 main executives

Most searched biographies at Zymeworks

• Kenneth Galbraith, Interim Chief Financial Officer and Chief Execu...
• Carlos Campoy, Director
• Brian Cherry, Director

Popular executive movements at Zymeworks

• Paul Schneider has joined the company as Executive Vice President and General Counsel  (posted on June 29 2026).
• Adam Schayowitz, who was Acting Chief Development Officer, is promoted to Executive Vice President, Head of Research and Development  (posted on April 12 2026).
• Scott Platshon, who was Acting Chief Investment Officer, is promoted to Executive Vice President, Chief Business Officer,  (posted on April 12 2026).

Click here to view some more movements at Zymeworks

Create your alert
to follow the executive moves at Zymeworks.

Zymeworks has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Zymeworks

• Zymeworks to Acquire Theravance Biopharma, Inc. | Zymeworks Inc.
• Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 | Zymeworks Inc.
• Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Jazz Pharmaceuticals plc
• Zymeworks Announces Participation in Upcoming Investor Conferences | Zymeworks Inc.
• Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock | Zymeworks Inc.
• Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results | Zymeworks Inc.
• Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Jazz Pharmaceuticals plc
• Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 | Zymeworks Inc.
• Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 | Zymeworks Inc.
• Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform | Zymeworks Inc.
• View more press releases Close

Social media about Zymeworks

• Zymeworks on Wikipedia, Google News & Yahoo Finance
• Zymeworks on LinkedIn, X (Twitter) & YouTube